Skip to content

The effect of repeated transcranial magnetic stimulation on the motor symptoms of Parkinson's disease in the cerebellum.

The effect of repeated transcranial magnetic stimulation on the motor symptoms of Parkinson's disease in the cerebellum.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101030
Enrollment
Unknown
Registered
2025-04-18
Start date
2025-04-25
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease

Interventions

Experimental group:One session of cTBS treatment was conducted in the left and right cerebellum respectively, once a day, with continuous stimulation for 5 days a week, followed by a 2-day rest, and t
Control group:One session of cTBS treatment was conducted in the left and right cerebellum respectively, once a day, with continuous stimulation for 5 days a week, followed by a 2-day rest, and then a

Sponsors

First Affiliated Hospital of Gannan Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis conforms to the Parkinson's disease diagnostic criteria of the International Movement Disorder Society (MDS) (2015); 2. Good cooperation and compliance; 3. Age range between 40-80 years old; 4. Right-handed (different handedness affects the dominant hemisphere and lateralization of the brain); 5. Normal mental state, capable of cooperating to complete scales and transcranial magnetic stimulation examinations; 6. Mini-Mental State Examination (MMSE) score >24 points; 7. Informed consent to all content of this study, participation in this research is voluntary and autonomous.

Exclusion criteria

Exclusion criteria: 1. Severe limb tremors or the presence of uncontrollable head tremors; 2. Metal objects or devices on the scalp or inside the body, such as cochlear implants, metal dentures, central venous catheters, pacemakers, etc.; 3. History of central nervous system conditions such as cerebral infarction, cerebral hemorrhage, leukoaraiosis, migraine, etc.; 4. Previously diagnosed with epilepsy or had epileptic seizures; 5. Have undergone neurosurgery, cerebral aneurysms, or arteriovenous malformations, etc.; 6. Comorbid with severe somatic diseases, such as liver and kidney function failure, heart failure, etc.; 7. Comorbid with vision, hearing, or speech impairments; 8. Comorbid with a history of mental illness or a family history of mental illness, such as schizophrenia, bipolar disorder, autism, mental retardation, severe depression, etc.; 9. History of drug abuse or drug use.

Design outcomes

Primary

MeasureTime frame
score of Movement Disorder Society - Unified Parkinson's Disease Rating Scale;Hoehn-Yahr scale;score of The 39 item Parkinson's disease questionnaire;

Countries

China

Contacts

Public ContactSong Zitan

First Affiliated Hospital of Gannan Medical University

songzitan1716@163.com+86 150 8372 1470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026